Defibrillators

Boston Scientific is now free to seek approvals for new devices in the $10 billion-a-year global market for pacemakers and implantable cardioverter "[T]he competitive dynamics have changed over the past year and it remains to be seen how successful and quickly (Boston Scientific) will be able to take back lost ICD market share," said Bank of America analyst Glenn Novarro.

Boston Scientific has yet to resolve a second warning letter about quality control problems at plants in Massachusetts, Minnesota and Indiana.

Sources: MarketWatch, Reuters, CNN.com, Bloomberg, 24/7 Wall Street Commentary: Bypassing Surgery - Will Stents Survive The Bad News?

• Boston Scientific Addresses Quality Issues at JPMorgan's HealthCare Conference • JNJ, Boston Scientific Heart Stents Are Safe, Says FDA Stocks/ETFs to watch: Boston Scientific Corp.

(BSX).

Competitors: Johnson & Johnson (JNJ), Medtronic Inc.

(MDT), St.

Jude Medical Inc.

(STJ), Abbott Laboratories (ABT).

ETFs: iShares Dow Jones US Medical Devices (IHI) Seeking Alpha's news briefs are combined into a pre-market summary called Wall Street Breakfast.

Get Wall Street Breakfast by email - it's free and takes only seconds to sign up.

Free Seeking Alpha Email Alerts Receive artic...

Read more...